Anti-Nivolumab Polyclonal Antibody
Product Specifications
Background
Durvalumab (Imfinzi) is a human IgG1 monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of cancer. It was developed by Medimmune/AstraZeneca. Durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody which blocks the interaction of PD-L1 with the PD-1 and CD80 molecules.Antibodysystem Anti-Durvalumab Antibody, pAb, Rabbit is produced from sera of a rabbit immunized with Durvalumab.
Host
Rabbit
Immunogen
Nivolumab
Target
Rabbit polyclonal to Opdivo.
Clonality
Polyclonal
Applications
ELISA
Purification
Purified by antigen affinity column.
Form
Liquid
Buffer
0.01M PBS, pH 7.4,50% Glycerol, 0.05% Proclin 300.
Storage Conditions
The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles.
Notes
Antibodysystem can customize this product per customer's request including product size, buffer components, etc. For research use only.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS7009274-01 0.02 mg
Recombinant Mycobacterium ulcerans ATP synthase subunit c (atpE)
Ask
View Details 
MBS7009274-02 0.1 mg
Recombinant Mycobacterium ulcerans ATP synthase subunit c (atpE)
Ask
View Details 
MBS7009274-03 5x 0.1 mg
Recombinant Mycobacterium ulcerans ATP synthase subunit c (atpE)
Ask
View Details 